524 related articles for article (PubMed ID: 14640773)
1. Safety of new phosphate binders for chronic renal failure.
Loghman-Adham M
Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphataemia in renal failure: causes, consequences and current management.
Albaaj F; Hutchison A
Drugs; 2003; 63(6):577-96. PubMed ID: 12656655
[TBL] [Abstract][Full Text] [Related]
4. Phosphate binder usage in kidney failure patients.
Bleyer AJ
Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
[TBL] [Abstract][Full Text] [Related]
5. Slowing the progression of vascular calcification in hemodialysis.
Chertow GM
J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
[TBL] [Abstract][Full Text] [Related]
6. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
7. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
Nagano N; Fukushima N
Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
Cizman B
Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
[TBL] [Abstract][Full Text] [Related]
10. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR; Qunibi WY
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of novel phosphate binders.
Querfeld U
Pediatr Nephrol; 2005 Mar; 20(3):389-92. PubMed ID: 15650884
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
[TBL] [Abstract][Full Text] [Related]
18. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres RamÃrez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
19. Medical management of secondary hyperparathyroidism in chronic renal failure.
Goodman WG
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii2-8. PubMed ID: 12771290
[TBL] [Abstract][Full Text] [Related]
20. Phosphate binders for control of phosphate retention in chronic renal failure.
Loghman-Adham M
Pediatr Nephrol; 1999 Oct; 13(8):701-8. PubMed ID: 10502131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
